A new combo therapy is shaking up the fight against aggressive myeloma! Patients with tough-to-treat extramedullary myeloma saw major improvements when treated with two bispecific antibodies—teclistamab and talquetamab. Nearly 79% responded to the treatment, and survival rates soared compared to standard options. Side effects? Mostly manageable. This could be a total game-changer for people who’ve run out of options. Science for the win! #Health #BodyHealth #Myeloma